Thomas 2002.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 130, breast, gastrointestinal, gynecological, other cancer; concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = if body weight > 45 kg 10000 IU sc TIW, if body weight < 45 kg 5000 IU sc TIW hb‐target = 12‐14 g/dL planned ESA duration = 12 weeks
Outcomes	Primary: Hb response; secondary: QoL, tumor response, survival, safety
Notes	study number = 84090
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Low risk	central randomization